• Custom Synthesis

  • Process Research and Development

  • Scale-Up

WHO WE ARE

CalChem Synthesis is a Contract Research Organization (CRO) serving as an outsourcing partner for the biotech and pharmaceutical companies and research institutions.

LEADERSHIP

Our leadership team has over 35 years of combined experience in different sectors of drug discovery and development in pharma industry.

OUR MISSION

Our mission is to set the highest standards in providing quality chemistry services at competitive prices to pharmaceutical and biotech companies for development of new drugs to cure diseases and promote better health for patients.

Experience

The chemistry activities at CalChem Synthesis are directed by Ph.D. level organic chemists with combined 35 years of experience in the pharmaceutical and chemical industries.

CalChem Synthesis (Where Chemistry makes a difference!)

  • Company Overview
    Company Overview
    CalChem Synthesis is a Contract Research Organization (CRO) serving as an outsourcing partner for the biotech and pharmaceutical companies and research institutions. Founded by Dr. Jalal Haddad, the co-founder of Pacific World Discovery, and a process research and development scientist at Albany Molecular Research, Inc. (AMRI), the company mission is to provide high quality non-GMP chemistry services to the chemical community and to maintain customer satisfaction. Our services are based on the belief that our customers’ needs are of the utmost importance and we are committed to meeting those needs. The experience of CalChem’s team in synthetic organic chemistry and process research Continue Reading...

News

  • U.S. Government Promises Takeda Up to $312M to Develop Zika Vaccine

    U.S. Government Promises Takeda Up to $312M to Develop Zika Vaccine. In the ongoing fight against Zika, the Biomedical Advanced Research and Development Authority (BARDA) has chosen to support Takeda Pharmaceutical Company’s Zika vaccine development, promising as much as $312 million in potential funding. According to the press release: Initial funding...

    Read more
View All